ATE437368T1 - Verfahren zum prüfen von mit wt1-verbundenen krankheiten - Google Patents

Verfahren zum prüfen von mit wt1-verbundenen krankheiten

Info

Publication number
ATE437368T1
ATE437368T1 AT01932243T AT01932243T ATE437368T1 AT E437368 T1 ATE437368 T1 AT E437368T1 AT 01932243 T AT01932243 T AT 01932243T AT 01932243 T AT01932243 T AT 01932243T AT E437368 T1 ATE437368 T1 AT E437368T1
Authority
AT
Austria
Prior art keywords
testing
disease
related diseases
course
value
Prior art date
Application number
AT01932243T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama filed Critical Haruo Sugiyama
Application granted granted Critical
Publication of ATE437368T1 publication Critical patent/ATE437368T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT01932243T 2000-05-24 2001-05-24 Verfahren zum prüfen von mit wt1-verbundenen krankheiten ATE437368T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000152923 2000-05-24
JP2001014927A JP3846199B2 (ja) 2000-05-24 2001-01-23 Ｗｔ１関連疾患の検査方法
PCT/JP2001/004353 WO2001090750A1 (fr) 2000-05-24 2001-05-24 Procédé d'examen d'une maladie liée au gene wt1

Publications (1)

Publication Number Publication Date
ATE437368T1 true ATE437368T1 (de) 2009-08-15

Family

ID=26592471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932243T ATE437368T1 (de) 2000-05-24 2001-05-24 Verfahren zum prüfen von mit wt1-verbundenen krankheiten

Country Status (11)

Country Link
US (2) US7824865B2 (de)
EP (2) EP1288661B1 (de)
JP (1) JP3846199B2 (de)
KR (3) KR20030014238A (de)
AT (1) ATE437368T1 (de)
AU (2) AU5882701A (de)
CA (2) CA2704596C (de)
DE (1) DE60139314D1 (de)
ES (2) ES2328107T3 (de)
PT (1) PT2045604E (de)
WO (1) WO2001090750A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP2007322211A (ja) * 2006-05-31 2007-12-13 Green Peptide Co Ltd がん患者の予後予測方法
CA2717036A1 (en) * 2008-02-28 2009-09-03 Martin Thurnher Methods for prognosing the status of tumor patients
RU2633068C2 (ru) * 2011-09-14 2017-10-11 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ измерения антитела против wt1
KR20160007579A (ko) * 2013-05-13 2016-01-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 면역요법의 임상 효과의 예측법
JP6537805B2 (ja) * 2014-10-29 2019-07-03 日本航空電子工業株式会社 レバー式コネクタ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP0846949B1 (de) 1996-04-16 2005-06-29 Kishimoto, Tadamitsu Verfahren zum nachweis solider krebszellen und histologischer heterotypien und verfahren zur prüfung von gewebe für die knochenmarktransplantation und die transplantation von peripheren blutstammzellen
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
US20030215458A1 (en) * 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma

Also Published As

Publication number Publication date
WO2001090750A1 (fr) 2001-11-29
KR20100095478A (ko) 2010-08-30
KR101056752B1 (ko) 2011-08-12
ES2389328T3 (es) 2012-10-25
EP1288661A1 (de) 2003-03-05
US7824865B2 (en) 2010-11-02
US20110124123A1 (en) 2011-05-26
AU2001258827B2 (en) 2005-06-09
KR20030014238A (ko) 2003-02-15
CA2704596A1 (en) 2001-11-29
DE60139314D1 (de) 2009-09-03
EP2045604B1 (de) 2012-08-29
CA2409208C (en) 2011-02-22
JP3846199B2 (ja) 2006-11-15
EP2045604A1 (de) 2009-04-08
AU5882701A (en) 2001-12-03
EP1288661A4 (de) 2006-07-05
CA2704596C (en) 2016-12-06
ES2328107T3 (es) 2009-11-10
US20050148037A1 (en) 2005-07-07
US9086415B2 (en) 2015-07-21
CA2409208A1 (en) 2001-11-29
EP1288661B1 (de) 2009-07-22
KR20080066862A (ko) 2008-07-16
KR101141319B1 (ko) 2012-05-04
JP2002048793A (ja) 2002-02-15
PT2045604E (pt) 2012-11-05

Similar Documents

Publication Publication Date Title
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
CY1112563T1 (el) Διαταξη και μεθοδος για τον ταυτοχρονο προσδιορισμο των αντιγονων των ομαδων του αιματος
DE60332639D1 (de) Verwendung von biomarkern zum nachweis von eierstockkrebs
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
DE69629292D1 (de) Verfahren zum feststellen der preparationsgüte von objektträgern und proben
DE60335813D1 (de) Verfahren zur krebsdiagnose mittels gpc3-nachweis
CO5280178A1 (es) Control de proceso usando detecciones multiples
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
DE602004019812D1 (de) Marker für neuromyelitis optica
DK0820522T3 (da) Assays og indretninger til detektering af ekstrahepatisk galdeatresi
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
PL1776587T3 (pl) Zastosowanie C3A i jego pochodnych jako biomarkera do leczenia gruczolaka i/lub raka jelita grubego; metody diagnostyczne i testy z ich użyciem
WO2005040759A3 (en) Apparatus and methods for detecting target analyte
ATE437368T1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten
ATE478337T1 (de) Methoden zum nachweis analyten in proben
ATE546527T1 (de) Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
DE50115528D1 (de) Verfahren zur identifizierung einer auf einen körper aufgebrachten markierung
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties